8.450USD-2.54%Mkt Cap: 519.19M USDP/E: —Last update: 2026-05-26
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap519.19M USD
Enterprise Value338.39M USD
Revenue (TTM)—
Gross Profit-126.36M USD
Net Income (TTM)-161.31M USD
Revenue/Share—
Last Price8.450 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees130
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.01
PEG—
EV/EBITDA-2.09
EV/Revenue—
P/S—
P/B2.75
EPS (TTM)-3.27
EPS (Forward)-2.95
52W Range
2.24054% of range13.67
52W High13.67 USD
52W Low2.240 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-69.45%
ROA-54.90%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-153.71M USD
CapEx (TTM)1.13M USD
FCF Margin—
FCF Yield-18.06%
Net Debt-202.69M USD
Net Debt/EBITDA1.25
Balance Sheet
Debt/Equity0.12
Current Ratio8.15
Quick Ratio7.97
Book Value/Sh3.231 USD
Cash/Share3.889 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)30.40 USD
Target Range25.00 USD – 33.00 USD
# Analysts5
Ownership
Shares Out.60.80M
Float35.50M
Insiders7.07%
Institutions74.05%
Short Interest
Short Ratio4.3d
Short % Float10.05%
Short % Out.8.53%
Shares Short5.16M
Short (prev mo.)4.21M
Technical
SMA 509.061 (-6.7%)
SMA 2007.424 (+13.8%)
Beta2.06
S&P 52W Chg28.31%
Avg Vol (30d)1.18M
Avg Vol (10d)1.05M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—